Recent advance in tailored treatment of gastric cancer.
- Author:
Hei Cheul JEUNG
1
;
Sun Young RHA
Author Information
1. Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
- Publication Type:Review ; Clinical Trial
- Keywords:
Gastric cancer;
Chemotherapy;
Tailored treatment;
Biological agent
- MeSH:
Asia;
Biological Agents;
Biomarkers;
Biology;
Chemotherapy, Adjuvant;
Humans;
Incidence;
Korea;
Mass Screening;
Molecular Biology;
Neoadjuvant Therapy;
Stomach Neoplasms;
Survival Rate
- From:Korean Journal of Medicine
2009;77(1):1-8
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Even the overall incidence is decreasing and the proportion of early gastric cancer is increasing from the national mass screening program, still gastric cancer is the major issue in Korea. Multimodality approach and the development of novel therapeutic agents enabled us to improve the survival rate of gastric cancer. However, the proper treatment strategy for the subgroups of patients is necessary, which is now categorized based on the clinicopathologic parameters. We need more in-depth information regarding the molecular biology of gastric cancer, and the development of novel targeted biological agents and the biomarkers for the future. Currently, the recent chemotherapeutic agents showed the improved response in advanced gastric cancer. Hence, the basic concept of adjuvant chemotherapy, palliative chemotherapy, neoadjuvant treatment with or without incorporation of radiotherapy become settle down with more evidences from several phase III trials. Especially, after understanding the difference between Asia and Western countries including biology, ethnic difference, operation technology, and the treatment approaches, the qualified, well-designed multinational clinical trials are on-going. Based on the current results, here, I describe the current status of gastric cancer treatment strategy.
